Phase 1 × Completed × Lymphoma, Large-Cell, Immunoblastic × Clear all Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)
Phase 1 Completed
41 enrolled
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Phase 1 Completed
16 enrolled
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
35 enrolled
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Phase 1 Completed
55 enrolled
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
Phase 1 Completed
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
Phase 1 Completed
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
Phase 1 Completed
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Phase 1 Completed
20 enrolled
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
Phase 1 Completed
34 enrolled
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 1 Completed
7 enrolled
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Phase 1 Completed
70 enrolled
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Phase 1 Completed
44 enrolled
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase 1 Completed
34 enrolled
DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
Phase 1 Completed
25 enrolled
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Phase 1 Completed
17 enrolled
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase 1 Completed
29 enrolled
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase 1 Completed
46 enrolled 11 charts
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
Phase 1 Completed
20 enrolled
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
Phase 1 Completed
5 enrolled
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 1 Completed
20 enrolled
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
Phase 1 Completed
89 enrolled
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
25 enrolled
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
25 enrolled
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Phase 1 Completed
27 enrolled
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1 Completed
20 enrolled
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
Phase 1 Completed
80 enrolled
Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma
Phase 1 Completed
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
Immunotoxin in Treating Patients With Leukemia or Lymphoma
Phase 1 Completed
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
Phase 1 Completed
24 enrolled
Flavopiridol in Treating Patients With Refractory Cancer
Phase 1 Completed
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
Phase 1 Completed
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma
Phase 1 Completed
15 enrolled
S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
66 enrolled
Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma
Phase 1 Completed
10 enrolled
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
Phase 1 Completed
23 enrolled
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Phase 1 Completed
30 enrolled
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Phase 1 Completed
30 enrolled
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
Phase 1 Completed
40 enrolled
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Phase 1 Completed
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
Phase 1 Completed
80 enrolled
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Phase 1 Completed
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
Phase 1 Completed
15 enrolled
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Phase 1 Completed
57 enrolled
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
12 enrolled
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 Completed
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
Phase 1 Completed